Kenvue Inc. $KVUE Shares Bought by Corbyn Investment Management Inc. MD

Corbyn Investment Management Inc. MD boosted its stake in shares of Kenvue Inc. (NYSE:KVUE) by 3.5% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 175,936 shares of the company’s stock after purchasing an additional 5,929 shares during the period. Kenvue makes up about 1.2% of Corbyn Investment Management Inc. MD’s portfolio, making the stock its 27th biggest position. Corbyn Investment Management Inc. MD’s holdings in Kenvue were worth $3,682,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also bought and sold shares of the stock. Trust Co. of Vermont increased its holdings in shares of Kenvue by 266.8% in the second quarter. Trust Co. of Vermont now owns 1,581 shares of the company’s stock valued at $33,000 after purchasing an additional 1,150 shares during the period. Truvestments Capital LLC purchased a new stake in Kenvue in the first quarter valued at approximately $37,000. Clal Insurance Enterprises Holdings Ltd boosted its position in Kenvue by 378.5% in the first quarter. Clal Insurance Enterprises Holdings Ltd now owns 1,627 shares of the company’s stock valued at $39,000 after buying an additional 1,287 shares during the last quarter. Bank Julius Baer & Co. Ltd Zurich increased its holdings in Kenvue by 120.6% in the 1st quarter. Bank Julius Baer & Co. Ltd Zurich now owns 1,699 shares of the company’s stock worth $41,000 after buying an additional 929 shares during the period. Finally, First Pacific Financial purchased a new position in Kenvue during the 2nd quarter worth approximately $54,000. Institutional investors and hedge funds own 97.64% of the company’s stock.

Kenvue Trading Down 0.1%

KVUE stock opened at $16.75 on Wednesday. Kenvue Inc. has a 12-month low of $14.02 and a 12-month high of $25.17. The business’s 50-day moving average is $16.61 and its 200 day moving average is $20.17. The company has a current ratio of 0.98, a quick ratio of 0.69 and a debt-to-equity ratio of 0.66. The stock has a market cap of $32.09 billion, a price-to-earnings ratio of 22.33, a PEG ratio of 2.45 and a beta of 0.71.

Kenvue (NYSE:KVUE) last released its earnings results on Monday, November 3rd. The company reported $0.28 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.27 by $0.01. Kenvue had a net margin of 9.55% and a return on equity of 20.02%. The business had revenue of $3.76 billion during the quarter, compared to analyst estimates of $3.83 billion. During the same quarter in the prior year, the firm earned $0.28 earnings per share. The company’s revenue for the quarter was down 3.5% compared to the same quarter last year. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. On average, sell-side analysts anticipate that Kenvue Inc. will post 1.14 EPS for the current fiscal year.

Kenvue Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, November 26th. Stockholders of record on Wednesday, November 12th will be given a dividend of $0.2075 per share. This represents a $0.83 annualized dividend and a dividend yield of 5.0%. The ex-dividend date of this dividend is Wednesday, November 12th. Kenvue’s payout ratio is presently 110.67%.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on KVUE shares. Jefferies Financial Group reduced their target price on shares of Kenvue from $25.00 to $23.00 and set a “buy” rating for the company in a report on Monday, October 27th. Edward Jones downgraded Kenvue from a “strong-buy” rating to a “hold” rating in a research report on Monday, November 3rd. Zacks Research raised Kenvue to a “strong sell” rating in a report on Monday, August 11th. Bank of America lowered their target price on Kenvue from $25.00 to $21.00 and set a “buy” rating on the stock in a research note on Wednesday, October 8th. Finally, Deutsche Bank Aktiengesellschaft set a $18.00 price target on Kenvue in a research report on Friday, October 24th. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, twelve have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $20.23.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.